Skip to main content
Fig. 4 | Arthritis Research & Therapy

Fig. 4

From: TRPA1 as a potential factor and drug target in scleroderma: dermal fibrosis and alternative macrophage activation are attenuated in TRPA1-deficient mice in bleomycin-induced experimental model of scleroderma

Fig. 4

Expression of M2-type macrophage markers in response to bleomycin treatment was lower in TRPA1-deficient mice. Expression of arginase-1 (A), MRC-1 (B), and IL-13 (C) mRNA in the skin from WT and TRPA1-deficient (TRPA1−/−) mice treated with bleomycin was measured by RT-PCR. The values of the mRNA of interest were normalized against GAPDH mRNA. WT control was given the value of 1 and the other values are set in the proportion to that value. Data are expressed as mean + SEM; n  =  6. *p < 0.05, **p < 0.01 between bleomycin treated WT and TRPA1-deficient mice; #p < 0.05, ##p < 0.01, ###p < 0.001 between control and bleomycin treated mice within the same genotype

Back to article page

Arthritis Research & Therapy

ISSN: 1478-6362

Contact us